STAT+: Regeneron’s George Yancopoulos talks CRISPR, obesity drugs, and the next generation of Covid antibody cocktails
The discovery of a rare genetic mutation that seems to protect certain people from becoming…
Category: The Readout LOUD
Listen: A CRISPR milestone, Biogen’s FDA saga, & George Yancopoulos on biotech in 2021
How much can CRISPR really do? Has the FDA been totally honest? And is it…
Listen: FDA inner workings, GSK’s foggy future, & the alarming rise in colorectal cancer
How does the FDA handle unprecedented decisions? What’s it like to go on “Good Morning…
Listen: The Covid vaccine booster debate, 23andMe hits Wall Street, & biotech’s call of the decade
Is 23andMe a tech company? Do we really need booster shots of Covid-19 vaccines? And…
Listen: Every angle on the FDA’s polarizing approval of Biogen’s Alzheimer’s drug
Was the FDA right to approve Aduhelm? What’s a fair price for a debatable drug?…
Listen: Fauci’s emails, FDA kremlinology, & covering the CRISPR babies scandal
Who is Anthony Fauci emailing at 3 a.m.? Does the FDA leave legible tea leaves?…
Grilling Scott Gottlieb on burgers, drugs, and a post-pandemic summer
Memorial Day weekend is around the corner, which means summer is finally here. Ahead of…
Listen: Scott Gottlieb on Covid and grilling, plus how Zolgensma has changed SMA
What does “one-and-done” treatment actually mean? Do we really need a permanent FDA commissioner? And…
Listen: Biotech meme stocks, the lessons of Spanish Flu, & becoming a pandemic celebrity
How do pandemics end? Who gets to be a TV media expert? And where does…
Listen: Lessons from a botched pandemic response, CDC sluggishness, & the future of health tech
Can we prevent the next Covid-19? Has the CDC become too cautious? And how many…
Listen: Vaccine riches, patent waivers, & a gene therapy for aging
What does $45 billion buy you these days? Is clinical trial tourism a business? And…
Virologist Angela Rasmussen on the controversy surrounding Russia’s Sputnik V Covid-19 vaccine
By all accounts, the Covid-19 vaccine developed by Russia’s Gamaleya Institute, called Sputnik V, has…
.jpg)
Listen: Biden’s punt on drug prices, Russia’s vaccine controversy, & the importance of tiny plastic cones
Does President Biden really care about drug prices? Is Sputnik V falling out of orbit?…
Listen: The latest mask debate, FDA in limbo, & gene therapy’s uncertain upside
When can we stop wearing masks outside? Are we ever getting a permanent FDA commissioner?…
‘We did need to throw a lot of spaghetti against the Covid window’: a biotech analyst on pandemic drug development
The pandemic has shined a spotlight on the biopharmaceutical industry, proving its value through the…
Listen: J&J’s vaccine pause, how to talk about remote risks, & why we don’t have new drugs for Covid-19
How do you describe a one-in-a-million risk? What’s heparin-induced thrombocytopenia? And why’s it so hard…
AstraZeneca’s latest vaccine woes, the compassionate use dilemma, & what it’s like to give out Covid vaccines
What’s next for AstraZeneca? Are there any right answers when it comes to compassionate use?…
.jpg)
Listen: Talkspace’s civic experiment, Illumina’s FTC headache, & remembering Gilead’s John Martin
Can an app replace in-person therapy? Is Illumina too big to Grail? And is another…
What to make of the AstraZeneca vaccine data — and the surrounding controversy
AstraZeneca’s up-and-down quest to develop a vaccine for Covid-19 stands out from what has otherwise…
AstraZeneca and the very good, then quite bad, then deeply confusing week
Who’s to blame for the AstraZeneca vaccine scandal? Can boldness backfire for pharma CEOs? And…
Vaccine acceptance expert weighs in on AstraZeneca saga
Over the past week, we’ve seen a domino effect in Europe with country after country…
Listen: Europe’s vaccine safety scare, Lilly’s Alzheimer’s data, & a plea for transparency
Has Europe lost the plot with Covid-19 vaccines? Can the latest treatment for Alzheimer’s disease…
Rooting for the home team: British journalist weighs in on U.K. vs. U.S. vaccine response
In the international race for Covid-19 vaccinations, the U.K. was first to a key milestone….
Listen: A U.K. take on Covid vaccines, the demise of Watson Health, and a ‘synbio’ explainer
Who is better at making and distributing Covid vaccines, the U.S. or the U.K.? What…
Listen: Peace among the pharma giants, the next phase of the pandemic, & a little Covid-19 optimism
Can pharma get along post-pandemic? How will we know when the Covid-19 crisis is over?…
Listen: Covid vaccines for teens, Novavax’s remarkable rise, and the future of HHS
Why can’t kids get Covid-19 vaccines? Is there hope for biotech penny stocks? And when…
Listen: Gene therapy’s safety scare, biotech’s brashest VCs, & the FDA’s uncertain future
How safe is gene therapy? Is there anything “unique” about venture capital? And who’s going…
The search for new Covid drugs — and a researcher’s reason for optimism
David Fajgenbaum is a physician and scientist at the University of Pennsylvania. He is best…
Listen: The state of the pandemic, the hunt for Covid-19 drugs, & meme stocks in biotech
When will we have enough vaccine doses? How many effective Covid-19 drugs are just waiting…
Listen: 23andMe is going public, vaccine data abound, and Merck’s CEO is retiring
Is consumer DNA testing a good business? Are Covid-19 vaccines interchangeable? And how do you…
Listen: J&J’s imminent vaccine data, CRISPR’s confusing boom, and navigating scientific misinformation
When are we getting more Covid-19 vaccine data? Is CRISPR having a dot-com moment? And…
Listen: Remembering STAT’s Sharon Begley
How do monkeys and Microsoft Word explain CRISPR? What does it mean to be “the…
Listen: JPM21: Déjà vu in Alzheimer’s research, debatable valuations in biotech, and OWS’s legacy
Is Alzheimer’s research stuck in a rut? Can genome editing live up to the hype?…
Listen: Biden’s plans for biopharma, a CES preview, & the next phase of the pandemic
What does a Democratic Senate portend for the drug industry? Is software eating health care?…
Listen: Moderna’s vaccine milestone, Warp Speed’s hurdles, and biotech in 2021
How long do Covid-19 vaccines last? Who should get them first? And when will we…
Listen: Pfizer’s Covid-19 vaccine: the debate, details, and distribution
Are Covid-19 vaccines safe for teens? Is the U.S. taking too long to authorize one?…
STAT+: A longtime health care investor on the wild ride of 2020 and what to expect in 2021
It’s time to talk about biotech and 2021. What will the year ahead look like…
AstraZeneca’s confusing vaccine data, biotech in 2021, and a guide to the ASH conference
Can too much Covid-19 vaccine be a bad thing? Is biotech in a bubble? And…
Listen: The latest Covid-19 vaccine data, Biden’s plans for the pandemic, and Bill Gates unfiltered
How do we measure whether Covid-19 vaccines work? What does Joe Biden think of the…
Listen: A road map for Covid-19, the gold rush in health tech, & D.C.’s pandemic unrest
Is superspreading an Olympic event? Will Covid-19 forever change health tech? And what are the…
Listen: The CDC’s credibility crisis, pandemic PR, and virtual conference malaise
How should governments talk about Covid-19? Can the Centers for Disease Control and Prevention rebuild…
Listen: AstraZeneca’s Covid-19 vaccine problem, charged coronavirus politics, and a recap of STAT’s Health Tech Summit
Is AstraZeneca’s Covid-19 vaccine in jeopardy? Why can’t politicians and scientists in Washington get along?…
FDA intrigue, Covid-19 vaccine timelines, and editing elected officials
Should the FDA commissioner resign? How fast can vaccine trials move? And what do Chelsea…
The FDA’s chaotic week, Trump’s effect on science, and Musk’s big reveal
Can the Food and Drug Administration survive Trump? Are drug reviewers in the deep state?…
Listen: Shocking FDA rejections, a setback in longevity science, & the latest on Covid-19 immunity
Did the FDA suddenly get stringent about new drugs? Is longevity research over-hyped? And what…
Covid-19 clinical trials are are failing to enroll diverse populations, despite awareness efforts
It’s been well-established that Covid-19, at least in the United States, has disproportionately affected people…
Listen: Pharma’s lobbying dollars, Alnylam’s future, and diversity in Covid-19 studies
Is pharma scared of Kamala Harris? Are there second acts in biotech? And why aren’t…
The story of a scientist’s mea culpa on Covid-19 vaccines — and a rough week on Twitter
The development of Covid-19 vaccines is progressing at an unprecedented speed. Vaccines that were mere…
Listen: A health tech mega-deal, a Twitter vaccine debate, and media criticism from Operation Warp Speed
Does the future of health tech look like Facebook? Can we cut corners with Covid-19…
Listen: Inside the NBA bubble, a DIY coronavirus vaccine, and the real VC numbers
How much should a Covid-19 vaccine cost? What can basketball teach us about pandemic safety?…